Forsight Robotics, an Israel-based developer of a robotic surgical platform for ophthalmic procedures, has raised $10 million. The seed round was led by Eclipse Ventures and joined by Mithril Capital.
The funding is earmarked to be used for expanding ForSight’s headcount and global reach as it sets its sights on launching its robotic surgery platform in multiple markets around the globe.
The company’s robotic surgical platform is designed to use microsurgical technology, advanced visualization and machine learning to produce automated ophthalmic procedures that offer precision and cost-effectiveness, according to the company’s website. From ForSight’s press release about the funding:
“ForSight’s robotics will provide unprecedented dexterity and maneuverability with six degrees of freedom, and the capability of executing intricate tasks with microsurgical instruments. Combining the latest advancements in robotics, machine learning and microsurgery, the ForSight system will incorporate state-of-the-art stereoscopic imaging technologies for surgical planning, real-time image guidance, and unparalleled visualization. The platform will ensure the continuous improvement of surgical technique and exceed human surgical capabilities with more precise movements of only a few microns.”
According to CTech, the company, which employs 15 people at present, was founded by Moshe Shoham, the founder of Mazor Robotics, which was bought by Medtronic for $1.7 billion.
Intuitive Surgical and Auris Health (now part of Johnson & Johnson) co-founder Dr. Fred Moll is on the ForSight’s strategic advisory board, as is Mako Surgical’s Rony Abovitz and Mithril’s Ajay Royan.
In addition, ForSight will be guided by a clinical advisory board comprising six world-renowned ophthalmic surgeons. They are Drs. David Chang, Elizabeth Yeu, Vance Thompson, Boris Malyugin, Sam Garg and Modi Naftali.
“We are thrilled to bring robotics into the world of ophthalmic surgery,” Dr. Glozman said. “Our goal is to democratize this highly sophisticated procedure, enabling patients around the world to easily access the treatment that can restore their vision.”
Tell Us What You Think!